Champions Oncology Reports Steady Revenue and New Leadership

Champions Oncology ( (CSBR) ) has released its Q1 earnings. Here is a breakdown of the information Champions Oncology presented to its investors.

Champions Oncology, Inc. is a global preclinical and clinical research services provider specializing in oncology R&D solutions for biopharma organizations, known for its extensive bank of patient-derived xenograft models and innovative bioanalytical platforms. In its latest earnings report for the first quarter of fiscal 2026, Champions Oncology reported a total revenue of $14 million, with an adjusted EBITDA of $60,000, marking a positive start to the fiscal year despite a slight decline in revenue compared to the previous year. Key highlights include the appointment of Rob Brainin as the new CEO, who aims to drive the company’s growth through its core services and emerging data platform, as well as a focus on scientific excellence and collaboration. Financially, the company experienced a loss from operations amounting to $527,000, primarily due to increased costs and operating expenses, including higher outsourced lab services and investments in its data licensing platform. Looking ahead, Champions Oncology’s management remains optimistic about continued revenue growth and margin improvement, supported by a strong services pipeline and increasing demand for its data offerings, positioning the company for long-term success.